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induced early, followed by C/EBP␣ and PPAR␥. It is widely
accepted that PPAR␥ is the master regulator of adipogenesis (2,
4). This conclusion is based mainly on the finding that forced
expression of PPAR␥ in C/EBP␣⫺/⫺ fibroblasts induces adipogenesis (5), whereas forced expression of C/EBP␣ in PPAR␥⫺/⫺
fibroblasts does not induce adipogenesis (6). Thus, the current
concept is that PPAR␥ is both necessary and sufficient for adipogenesis. No other factor is known that can induce adipogenesis in the absence of PPAR␥ (7). Here we report that a newly
discovered zinc finger protein, MCP-1-induced protein
(MCPIP) (8), induces adipogenesis in the absence of PPAR␥. In
an engineered tissue model, MCP-1 treatment was reported to
enhance adipose tissue volume (9). In 3T3-L1 cells undergoing
adipogenesis in the commonly used adipogenesis-inducing
medium, containing dexamethasone, 3-isobutyl-1-methylxanthine, and insulin (DMI), MCP-1 is produced, and MCPIP is
induced before the induction of the C/EBP family of transcription factors and PPAR␥. Knockdown of MCPIP with siRNA
inhibits induction of these genes and adipogenesis. Treatment
of 3T3-L1 cells with MCP-1 or forced expression of MCPIP
induces adipogenesis without the adipogenesis-inducing DMI
medium. Forced expression of MCPIP induces adipogenesis in
PPAR␥⫺/⫺ mouse embryonic fibroblasts (MEF). Thus, MCPIP
is a newly identified inducer of adipogenesis.

The incidence of obesity and associated diseases is increasing
dramatically throughout the world. The global incidence of
type 2 diabetes is projected to double to 350 million cases by the
year 2030 (1). Because adipose tissue serves as a crucial integrator of glucose homeostasis, understanding of adipocyte biology
is crucial for understanding the pathophysiological basis of
obesity and related metabolic diseases (2, 3). Adipogenesis and
angiogenesis, which supply blood to the growing adipose tissue,
occur in the growing adipose tissue when the caloric intake
significantly exceeds caloric expenditure. Adipogenesis involves a temporally regulated set of gene expression controlled
by a set of transcription factors (3, 4). C/EBP␤2 and C/EBP␦ are

EXPERIMENTAL PROCEDURES
Cell Culture—The 3T3-L1 fibroblast cell line was obtained
from the American Type Culture Collection (ATCC).
PPAR␥⫺/⫺ MEF cell line was obtained from Dr. Bruce
Spiegelman, Harvard University. Cells were maintained in Dulbecco’s modified Eagle’s medium with 1% penicillin/streptomycin and 10% fetal bovine serum until experimentation. Cells
growing on plates at 60% confluency were treated with or without 10 ng/ml MCP-1 for 7 days. Adipocyte differentiation was
induced by replacing Dulbecco’s modified Eagle’s medium with
media containing DMI (Zen-Bio, Inc.). Construction of the
MCPIP-GFP expression plasmid has been described previously
(8). Cells were transfected with 100 nmol/liter of a chemically
synthesized siRNA targeted for MCPIP (Ambion) or with 100
nmol/liter nonspecific siRNA (Ambion) 12 h prior to treatment
with DMI. All cells types were transfected using FuGENE HD
(Roche Applied Science).
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LPL, lipoprotein lipase; MCPIP, MCP-1-induced protein; MEF, mouse
embryonic fibroblasts; RT, reverse transcription; siRNA, small interfering
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RNA; GFP, green fluorescent protein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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Adipogenesis is a key differentiation process relevant to obesity and associated diseases such as type 2 diabetes. This process
involves temporally regulated genes controlled by a set of transcription factors, CCAAT/enhancer-binding proteins (C/EBP)
␤, C/EBP␦, and C/EBP␣ and peroxisome proliferator-activated
receptor ␥ (PPAR␥). Currently, PPAR␥ is universally accepted
as the master regulator that is necessary and sufficient to induce
adipogenesis as no known factor can induce adipogenesis without PPAR␥. We present evidence that a novel zinc finger protein, MCP-1-induced protein (MCPIP), can induce adipogenesis without PPAR␥. Classical adipogenesis-inducing medium
induces MCP-1 production and expression of MCPIP in 3T3-L1
cells before the induction of the C/EBP family of transcription
factors and PPAR␥. Knockdown of MCPIP prevents their
expression and adipogenesis as measured by expression of adipocyte markers and lipid droplet accumulation. Treatment of
3T3-L1 cells with MCP-1 or forced expression of MCPIP
induces expression of C/EBP␤, C/EBP␦, C/EBP␣, and PPAR␥
and adipogenesis without any other inducer. Forced expression
of MCPIP induces expression of the C/EBP family of transcription factors and adipogenesis in PPAR␥ⴚ/ⴚ mouse embryonic
fibroblasts. Thus, MCPIP is a newly identified protein that can
induce adipogenesis without PPAR␥.

Adipogenesis Induction by MCPIP without PPAR␥
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FIGURE 1. 3T3-L1 fibroblasts produced MCP-1 when treated with DMI, and MCP-1 treatment of 3T3-L1 fibroblasts induced MCPIP expression and
adipogenesis. A, 3T3-L1 cells were treated with or without DMI. RNA was isolated, and MCP-1 transcript levels were measured using real time RT-PCR (* ⫽ p ⬍
0.02). ⫺⌬⌬Ct values of treated/untreated are displayed. B, 3T3-L1 cells grown to 60% confluency were treated with or without 10 ng/ml MCP-1 protein for 7
days. RNA and cell lysate were collected 1, 3, 5, and 7 days after treatment. Transcript levels of the adipogenesis markers C/EBP␤, C/EBP␦, C/EBP␣, and PPAR␥
were measured using real time RT-PCR (* ⫽ p ⬍ 0.02; # ⫽ p ⬍ 0.03). C, protein levels of C/EBP␤, C/EBP␦, C/EBP␣, and PPAR␥ were measured using immunoblot
analysis. Results were quantified against GAPDH. D, RNA and cell lysate were collected 7 days after MCP-1 treatment. Real time RT-PCR was used to measure the
adipogenesis markers adiponectin (Adipo), LPL, and AP2 (normalized to ␤-actin, ⫺⌬⌬Ct values of treated/untreated are displayed; * ⫽ p ⬍ 0.02). E, protein
levels of adiponectin, LPL, and AP2 were measured using immunoblot analysis. Results were quantified against GAPDH (* ⫽ p ⬍ 0.02). F, cells were stained with
Oil Red-O 8 days after MCP-1 treatment. G, MCPIP transcript levels were measured using real time RT-PCR (normalized to ␤-actin, ⫺⌬⌬Ct values of treated/
untreated are displayed). Protein levels of MCPIP were measured using immunoblot analysis. Results were quantified against GAPDH (* ⫽ p ⬍ 0.02; # ⫽ p ⬍
0.03). All experiments were repeated three times.
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Oil Red-O—3T3-L1 or PPAR␥⫺/⫺ MEF cells were fixed with
10% formalin for 30 min at room temperature 8 days after
experimental treatment. Cells were then washed with 60% isopropyl alcohol followed by treatment with Oil Red-O (2.1
mg/ml) for 20 min at room temperature. Samples were then
washed four times with H2O. Images of sample plates stained
with Oil Red-O were taken and analyzed using morphometric
software analysis. Oil Red-O was evaluated by measuring total
objects stained, area of plate stained, and total intensity of
stained area. All three methods yielded similar results. After
examining the plates microscopically, they were treated with
100% isopropyl alcohol to extract Oil Red-O. The solution was
then measured for absorbance at 520 nm.
RT-PCR—Total RNA was isolated from treated fibroblasts
using TRIzol (Invitrogen). First-strand cDNA was synthesized
using 1 g of total RNA (DNase-treated) using the RT cDNA
synthesis kit (High Capacity, Applied Biosystems). ␤-Actin
served as internal control. The primer set forward 5-ctccaatgttctcaaacttac-3⬘ and reverse 5⬘-gtattcctatggcttccagtgc-3⬘ was

27622 JOURNAL OF BIOLOGICAL CHEMISTRY

used to detect a 400-bp product in the PPAR␥⫺/⫺ MEF cell line
to confirm the deletion of exon 2 in PPAR␥ (9).
Immunoblot Analysis—3T3-L1 and PPAR␥⫺/⫺ MEFs were
treated with cell lysis buffer (20% glycerol, 0.1% Triton X-100,
8% 0.5 M EDTA, and 1% 1 M dithiothreitol), and protein samples
were collected and subjected to immunoblot using polyclonal
antibodies specific for MCPIP (1:2000), C/EBP␣ (1:2000),
C/EBP␤ (1:2000, Abcam), C/EBP␦ (1:2000, Abcam), PPAR␥
(1:2000, Abcam), adiponectin (1:3000, Abcam), LPL (1:2000,
Abcam), aP2 (1:2000, Abcam), and apelin (1:3000, Abcam).
Rabbit secondary antibody was used at a concentration of
1:5000 except for aP2, which used a chicken secondary antibody
at a concentration of 1:5000.

RESULTS
We recently reported that MCP-1 binding to CCR2 leads to
the induction of a novel zinc finger protein, called MCPIP, that
can induce cell death (8) or differentiation leading to angiogenesis (10). MCP-1 production by preadipocytes has been
VOLUME 284 • NUMBER 40 • OCTOBER 2, 2009
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FIGURE 2. DMI-induced adipocyte differentiation of 3T3-L1 fibroblast cells elicited an early increase in MCPIP expression. 3T3-L1 fibroblasts were
treated with or without DMI. RNA was collected at 1– 4 days after treatment. Real time RT-PCR was used to measure MCPIP (A), and the known adipogenesis
markers C/EBP␤ (B), C/EBP␦ (C), C/EBP␣ (D), and PPAR␥ (E). Results were normalized to ␤-actin; ⫺⌬⌬Ct values of treated/untreated are displayed (* ⫽ p ⬍ 0.02).
F, immunoblot analysis was performed with cell lysate collected at the same time points with antibodies against MCPIP, C/EBP␤, C/EBP␦, C/EBP␣, and PPAR␥,
G–K, results in F were quantified against GAPDH (* ⫽ p ⬍ 0.02; # ⫽ p ⬍ 0.03; error bars ⫽ p ⬍ 0.05). All experiments were repeated three times.

Adipogenesis Induction by MCPIP without PPAR␥

detected (11), and in a tissue engineering model of adipogenesis
MCP-1 treatment was reported to increase adipose tissue mass
in vivo (9). In view of these observations that suggest the possibility of a role for MCP-1 in adipogenesis, we tested whether
differentiation of 3T3-L1 cells into adipocytes involves MCP-1.
First, we tested whether 3T3-L1 cells were induced to produce
MCP-1 by DMI medium. Real time RT-PCR showed that
MCP-1 transcript level reached maxima 4 h after treatment
with DMI medium compared with non-DMI-containing
medium (Fig. 1A). We then tested whether MCP-1 treatment
could induce differentiation of 3T3L-1 cells into adipocytes in a
non-DMI-containing medium. MCP-1 treatment induced
OCTOBER 2, 2009 • VOLUME 284 • NUMBER 40

expression of the C/EBP family of transcription factors and
PPAR␥ that is known to be induced during differentiation of
3T3-L1 cells into adipocytes (Fig. 1B). C/EBP␤ and C/EBP␦
were induced early followed by induction of C/EBP␣ and
PPAR␥. Induction of these adipogenesis-associated transcription factors was clearly seen at the transcript level determined
by real time PCR analysis and at the protein level as determined
by immunoblot analysis (Fig. 1, B and C). MCP-1 treatment
induced adipocyte markers. Induction of adiponectin, LPL, and
AP2 was clearly seen at the transcript level determined by real
time PCR and protein level as determined by immunoblot analysis (Fig. 1, D and E). Microscopic examination revealed lipid
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 3. Knockdown of MCPIP inhibited DMI-induced adipogenesis. 3T3-L1 fibroblasts were treated with siRNA specific for MCPIP for 24 h before
treatment with DMI. A, RNA was isolated from all samples 7 days after DMI treatment and was evaluated for transcript levels for the adipocyte markers,
adiponectin, and LPL by using RT-PCR; ␤-actin served as a control. B, immunoblot analysis was performed with cell lysate collected from all samples 7 days after
DMI treatment. The samples were evaluated for the adipocyte markers adiponectin and LPL. C, results in B were quantified against GAPDH (* ⫽ p ⬍ 0.02; # ⫽
p ⬍ 0.03). NS siRNA, nonspecific (scrambled) siRNA. D–G, RNA was isolated from samples 1– 4 days after DMI treatment. Real time RT-PCR was used to measure
transcript levels of C/EBP␤, C/EBP␦, C/EBP␣, and PPAR␥. ␤-Actin served as a control; ⫺⌬⌬Ct values of treated/untreated are displayed. * ⫽ p ⬍ 0.02; # ⫽ p ⬍
0.03. H, cells were stained with Oil Red-O 8 days after treatment with DMI. All experiments were repeated three times.
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FIGURE 4. Forced expression of MCPIP-induced adipogenesis without DMI in 3T3-L1 cells. 3T3-L1 fibroblasts were transfected with MCPIP-GFP or GFP
alone. RNA and cell lysate were collected 0.5, 1, 3, and 5 days after transfection. Transcript levels of MCPIP (A), and the adipogenesis markers C/EBP␤ (B), C/EBP␦
(C), C/EBP␣ (D), and PPAR␥ (E) were measured using real time RT-PCR (normalized to ␤-actin; ⫺⌬⌬Ct values of MCPIP-GFP/GFP are displayed; * ⫽ p ⬍ 0.02; # ⫽
p ⬍ 0.03; error bars ⫽ p ⬍ 0.05). F, protein levels of MCPIP, C/EBP␤, C/EBP␦, C/EBP␣, and PPAR␥ were measured using immunoblot analysis. G–K, results in F were
quantified against GAPDH (* ⫽ p ⬍ 0.02). RNA and cell lysate were collected 7 days after transfection. L, transcript levels of the adipocyte markers, adiponectin
and LPL, were measured using RT-PCR; ␤-actin served as a control; ⫺⌬⌬Ct values of MCPIP-GFP/GFP are displayed. M, protein levels of the adipocyte markers,
adiponectin and LPL, were measured using immunoblot analysis. N and O, results in M were quantified against GAPDH (* ⫽ p ⬍ 0.02). P, cells were stained with
Oil Red-O 8 days after transfection. All experiments were repeated three times.
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FIGURE 5. Treatment of 3T3-L1 cells with MCP-1 or transfection with
MCPIP-GFP resulted in oil droplet accumulation comparable with 3T3-L1
cells treated with the classical mixture DMI. 3T3-L1 fibroblasts were
treated with DMI or MCP-1 or were transfected with MCPIP-GFP. Cells were
stained with Oil Red-O 8 days after treatment. Images of plates were captured,
and staining was measured using morphometric software analysis. Quantitation of lipid accumulation in the entire plate was done on the basis of total
stained area, number of cells stained, and intensity of staining. All three methods yielded similar results. The results obtained on the basis of total area
stained are displayed.

days in non-DMI medium showed strong staining of lipid bodies, whereas GFP controls showed no staining (Fig. 4P). Thus it
is clear that MCPIP expression can induce adipogenesis in
3T3-L1 cells in the absence of the usual adipogenesis-inducing
factors in the medium. MCP-1 treatment and forced expression
of MCPIP in non-DMI medium caused accumulation of lipid
droplets comparable with that observed in the DMI medium,
although the DMI medium induced the most robust degree of
lipid droplet accumulation. This conclusion is based on morphometric quantitative analysis of the stained plates (Fig. 5).
In view of the currently held view that adipogenesis cannot
be induced in the absence of PPAR␥, we tested whether forced
expression of MCPIP can induce adipogenesis in PPAR␥⫺/⫺
MEFs. We transfected PPAR␥⫺/⫺ cells with MCPIP-GFP
expression plasmids or GFP control and incubated them in
DMI medium. Forced expression of MCPIP in PPAR␥⫺/⫺ cells
caused induction of the C/EBP family of transcription factors,
C/EBP␤, C/EBP␦, and C/EBP␣, as seen both at the transcript
level as measured by real time PCR (Fig. 6A) and at protein level
as measured by immunoblot analysis (Fig. 6, B–E). The MCPIPGFP-transfected cells exhibited adipogenesis as indicated by
induction of adipocyte markers, Ap2, adiponectin, and LPL, as
measured by immunoblot analysis (Fig. 6, F and G), whereas
GFP controls showed very little induction. Microscopic examination of the Oil Red-O-stained cells showed robust accumulation of lipid droplets in MCPIP-GFP-transfected PPAR␥⫺/⫺
cells, whereas GFP controls showed little lipid accumulation
(Fig. 6H). Because this result is contrary to the currently
accepted view that PPAR␥ is necessary for adipogenesis, we
confirmed that the PPAR␥⫺/⫺ MEFs we used were, in fact,
PPAR␥⫺/⫺ as reported by the authors who generated this
PPAR␥ null cell line (12) and as indicated under “Experimental
Procedures.” Immunoblot analysis confirmed the absence of
JOURNAL OF BIOLOGICAL CHEMISTRY
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body accumulation. Oil Red-O staining revealed robust accumulation of lipid bodies (Fig. 1F). We tested whether MCP-1induced adipogenesis is mediated via MCPIP. Upon MCP-1
treatment, MCPIP was induced to a maximal level during the
1st day (Fig. 1G). This induction was clear from real time PCR
measurement of the transcript level and from the immunoblot
analysis of MCPIP protein level. After the 2nd day MCPIP levels
decreased. This result is consistent with the involvement of
MCPIP in adipogenesis.
If MCPIP is a key player in adipogenesis, it should be induced
early during the adipocyte differentiation and induced in
3T3-L1 cells by the commonly used adipogenesis-inducing
DMI medium. The levels of MCPIP, C/EBP␤, and C/EBP␦
reached maximal levels during the first 2 days. Induction of
PPAR␥ and C/EBP␣ followed as expected (Fig. 2). That MCPIP
plays a critical role in adipogenesis is indicated by the finding
that knockdown of MCPIP expression with siRNA specific for
MCPIP inhibited adipogenesis induced by DMI medium,
whereas nonspecific (scrambled) siRNA had very little effect
(Fig. 3, A–H). This inhibition was demonstrated by the inhibition of appearance of adipocyte markers adiponectin and LPL
at the transcript level as indicated by real time RT-PCR (Fig. 3A)
and at the protein level as measured by immunoblot analysis
(Fig. 3, B and C). In addition, real time RT-PCR measurements
of transcript levels showed that knockdown of MCPIP expression resulted in inhibition of induction of the known adipogenesis-associated transcription factors C/EBP␤, C/EBP␦,
C/EBP␣, and PPAR␥ (Fig. 3, D–G). Staining of the cells with Oil
Red-O after 8 days of differentiation in DMI medium showed
that knockdown of MCPIP by treatment with siRNA, specific
for MCPIP, drastically inhibited lipid droplet accumulation,
whereas nonspecific siRNA had little effect (Fig. 3H). Measurement of Oil Red-O extracted from stained cells also shows that
knockdown of MCPIP inhibited lipid accumulation (data not
shown). These results suggest that MCPIP plays a critical role in
adipogenesis induced by DMI.
If MCPIP is one of the critical regulators involved in adipogenesis, forced expression of MCPIP in 3T3-L1 cells might be
expected to cause induction of adipogenesis in the absence of
adipogenesis-inducing DMI mixture. Transfection of 3T3-L1
cells with an expression construct for MCPIP-GFP caused the
induction of adipogenesis in the absence of DMI medium,
whereas GFP controls did not show differentiation (Fig. 4).
Forced expression of MCPIP induced the expression of the well
established cascade of gene expression known to occur in DMI
medium. MCPIP expression induced C/EBP␤, C/EPB␦,
C/EBP␣, and PPAR␥, the transcription factors well known to be
involved in adipogenesis. The induction of these transcription
factors was seen both at the transcript levels measured by real
time RT-PCR (Fig. 4, B–E) and at a protein level measured by
immunoblot analyses (Fig. 4, F–K). C/EBP␤ and C/EBP␦ levels
reached maximal levels before C/EBP␣ and PPAR␥ levels
reached maximal levels as seen in DMI medium. MCPIP-induced adipogenesis was demonstrated by the induction of adipocyte markers, adiponectin and LPL, both at the transcript
level as indicated by real time RT-PCR and at protein level as
measured by immunoblot analysis (Fig. 4, L–O). Staining of the
cells transfected with MCPIP-GFP expression plasmid, after 8
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PPAR␥ protein (Fig. 6I). Thus, MCPIP expression can induce
adipogenesis in the absence of PPAR␥.

FIGURE 6. Forced expression of MCPIP in PPAR␥ⴚ/ⴚ fibroblasts induced adipogenesis. PPAR␥⫺/⫺ fibroblasts were transfected with MCPIP-GFP or GFP
alone and were evaluated for adipogenesis. A, RNA was collected from PPAR␥⫺/⫺ fibroblasts 1, 3, and 5 days after transfection with MCPIP-GFP or GFP alone.
Transcript levels of C/EBP␤, C/EBP ␦, and C/EBP␣ were evaluated using real time RT-PCR; ␤-actin served as a control; ⫺⌬⌬Ct values of MCPIP-GFP/GFP are
displayed (* ⫽ p ⬍ 0.02). B, cell lysate was collected from the same samples and were evaluated via immunoblot for C/EBP␤, C/EBP␦, and C/EBP␣. C–E, results
in B were quantified against GAPDH (* ⫽ p ⬍ 0.02; # ⫽ p ⬍ 0.03). F, immunoblot analysis was performed with cell lysate collected from all samples 1, 3, 5, and
7 days after transfection. Samples were evaluated for the adipocyte markers AP2, adiponectin, and LPL. G, results in A were quantified against GAPDH (* ⫽ p ⬍
0.02). H, cells were treated with Oil Red-O 8 days after transfection and were microscopically evaluated. I, PPAR␥⫹/⫹ or PPAR␥⫺/⫺ fibroblasts were transfected
with MCPIP-GFP. Samples were evaluated for PPAR␥ using immunoblot analysis. All experiments were repeated three times.
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DISCUSSION
The results presented here constitute the discovery of a
previously unknown key player that can induce adipogenesis
in the absence of PPAR␥ that is currently thought to be necessary and sufficient for adipogenesis. The central role of
MCPIP in adipogenesis was demonstrated by the finding
that MCP-1 production was induced very early after 3T3-L1
cells were placed in DMI medium. Furthermore, MCP-1
treatment of 3T3-L1 cells induced adipogenesis. This direct
demonstration of MCP-1 induction of adipogenesis is consistent with a recent report that MCP-1 enhanced new adipose tissue formation in vivo (9). Adipogenic precursor cells
are known to have CCR2 (13). Because MCPIP is induced by
the signaling process resulting from MCP-1 interaction with
its receptor CCR2 (8), the present results have implications
on the role of MCP-1/CCR2 in obesity and type 2 diabetes. In
diet-induced insulin resistance, mcp-1 gene expression in
adipose tissue increases in ob/ob and db/dp mice (14). Adipocyte-specific overexpression of MCP-1 in mice results in
increased macrophage recruitment to adipose tissue and
causes hepatic steatosis and insulin resistance in liver and
muscle as well as fat tissue. In CCR2⫺/⫺ mice, recruitment of
monocytes/macrophages into adipose tissue is inhibited,
and development of obesity-induced insulin resistance is
attenuated (15). Macrophage recruitment and consequent
inflammatory response in adipose tissue result in secretion
of more MCP-1, tumor necrosis factor-␣, and interleukin-␤
(16). These agents cause increase in lipolysis and decrease in
triacylglycerol synthesis leading to increased levels of fatty
acids and in the availability of triacylglycerols for uptake
directly into skeletal muscle (3). These excess circulating
lipids cause accumulation of fatty acyl-CoA in skeletal muscle, liver, and ␤ cells leading to insulin resistance and type 2
diabetes (17, 18). The inflammatory stress causes interleukin-6 secretion from the adipose tissue that leads to expression of suppressor of cytokine signaling expression that is
known to induce hepatic insulin resistance (19). Thus, there
is strong evidence for a key role that MCP-1/CCR2 system
plays in obesity and type 2 diabetes. The role of MCP-1 in
this process has been questioned on the basis that macrophage accumulation in adipose tissue was not significantly
attenuated in MCP-1-deficient mice (20). However, MCP-5
can substitute as a CCR2 ligand in mice (21).
The exact source of MCP-1 in adipose tissue is not known,
although there are several possibilities. Obesity is well
known to cause elevation of MCP-1 levels. The resident macrophages and macrophages infiltrating the adipose tissue

could produce MCP-1. MCP-1 production could also be
caused by endotoxemia from gut flora elevated by feeding
(22). Death of adipocytes could release MCP-1, as dying cells
are known to release MCP-1 (23). Adipose tissue in obese
animals is reported to have localized hypoxia that could lead
to hypoxia-inducible factor induction and MCP-1 production (24, 25). We have found that under hypoxia human macrophages secrete MCP-1. In adipose tissue macrophage-containing areas were found to be hypoxic, and thus these
macrophages would also produce MCP-1.
We show that MCP-1 binding to CCR2, which is known to be
present in fibroblasts and preadipocytes (13, 26), caused
MCPIP induction before C/EBP␤ and C/EBP␦ were induced.
Furthermore, knockdown of MCPIP expression inhibited the
induction of these transcription factors and drastically inhibited adipogenesis. Forced expression of MCPIP induced the
cascade of transcription factors well known to be induced by
DMI medium leading to robust adipogenesis. Thus MCPIP
expression induced adipogenesis via the already known
sequence of induction of transcription factors and expression of adipogenesis markers. MCPIP induction is one of the
earliest events in adipogenesis, and MCPIP-induced adipogenesis was associated with PPAR␥ induction. What was
surprising was that MCPIP expression could induce adipogenesis in PPAR␥⫺/⫺ cells in which no other factor has previously been able to induce adipogenesis. This finding shows
that MCPIP is a key regulator of adipogenesis.
How exactly MCPIP induces the expression of the C/EBP
family of transcription factors that would lead to adipogenesis
remains to be elucidated. Considering the finding that MCPIP
is induced before the induction of the C/EBP family, it appears
possible that the role of MCPIP is to induce the early transcriptions factors C/EBP␤ and C/EBP␦, which would then lead to the
induction of subsequent factors required for adipogenesis.
C/EBP␣ and PPAR␥ can induce each other. However, C/EBP␣
cannot induce adipogenesis without PPAR␥. Our results demonstrate that MCPIP can induce C/EBP␣ and adipogenesis
without PPAR␥. Thus, MCPIP can be considered a critical regulator of adipogenesis.
There is overwhelming evidence that demonstrates a key role
for CCR2-mediated events in obesity and development of type 2
diabetes. Our results show that the MCP-1/CCR2 system plays
a direct role in adipogenesis. There is experimental evidence
that MCP-1 can promote angiogenesis (27, 28) and that this
MCP-1-induced angiogenesis is mediated via MCPIP (10).
Thus, MCPIP induced by MCP-1/CCR2 interaction promotes
adipogenesis and angiogenesis to supply blood to growing adipose tissue. These findings help provide a molecular basis for

Adipogenesis Induction by MCPIP without PPAR␥
the role of the MCP-1/CCR2 system in the development of
obesity and consequent development of type 2 diabetes.
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